Skip to main content
. 2016 Jan 4;291(11):5500–5511. doi: 10.1074/jbc.M115.691162

TABLE 4.

Inhibition of VEGF-A165 binding to VEGFR1 and VEGFR2 by VEGF dual dAb and aflibercept

Data are the mean from n = 3 experiments, except bevacizumab (R1, n = 3; R2, n = 11) and ranibizumab (R2, n = 2) determined by MSD (numbers in parentheses represent S.D.).

Molecule VEGFR1 IC50 VEGFR2 IC50
pm pm
Aflibercept 75 (10.2) 32 (3.5)
VEGF dual dAb 59 (11.8) 22 (2.7)
Bevacizumab 2204 (82.0) 2661 (1279)
Ranibizumab NDa 1166 (124.9)

a ND, not determined.